Dr. Gurjar is currently developing a small molecule inhibitor for the treatment of triple negative breast cancer at Stanford ChEM-H Medicinal Chemistry Knowledge Center with Drs. Mark Smith and Michal Clarke. Prior to joining Stanford, he obtained his PhD in Chemistry from the lab of Prof. Valery Fokin, founder of copper-catalyzed azide-alkyne (CuAAC) click chemistry, at the University of Southern California. His research focused on developing new click reactions and their applications spanning across small molecule inhibitors to materials chemistry.

Stanford Advisors